Corrigendum re "A Preoperative Nomogram to Predict Renal Function Insufficiency for Cisplatin-based Adjuvant Chemotherapy Following Minimally Invasive Radical Nephroureterectomy (ROBUUST Collaborative Group)" [Eur Urol Focus 2022;8:173-81]

Affiliations

• ¹ Department of Urology, Changzheng Hospital, Naval Medical University, Shanghai, China.
• ² Department of Health Statistics, Naval Medical University, Shanghai, China.
• ³ Institute of Urology & Catherine and Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
• ⁴ Department of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy.
• ⁵ Division of Urologic Oncology, Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.
• ⁶ Indiana University School of Medicine, Indianapolis, IN, USA.
• ⁷ Department of Urology, Urological Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.
• ⁸ Department of Urology, University of Miami Miller School of Medicine, Miami, FL, USA.
• ⁹ Icahn School of Medicine at Mount Sinai, Department of Urology, New York, NY, USA.
• ¹⁰ OLV Hospital, Aalst, Belgium; ORSI Academy, Melle, Belgium.
• ¹¹ Vattikuti Urology Institute, Henry Ford Hospital, Detroit, MI, USA.
• ¹² Swedish Medical Center, Seattle, WA, USA.
• ¹³ Department of Urology, Temple University, Philadelphia, PA, USA.
• ¹⁴ Department of Urology, UCSD, San Diego, CA, USA.
• ¹⁵ Division of Urology, VCU Health, Richmond, VA, USA.
• ¹⁶ IRCCS "Regina Elena" National Cancer Institute, Department of Urology, Rome, Italy.
• ¹⁷ Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
• ¹⁸ Division of Urology - European Institute of Oncology, IRCCS, Milan, Italy.
• ¹⁹ Department of Urology, Changzheng Hospital, Naval Medical University, Shanghai, China. Electronic address: wanglinhui@smmu.edu.cn.